Drug Czar Says Cannabis Is 'Still Illegal' After Schedule III Rescheduling: What It Actually Means

The Drug Czar's "Still Illegal" Statement

Let's start with the obvious question: why would the White House drug czar feel the need to clarify this? The answer lies in the massive gap between what the public heard and what actually happened. When news broke in late April that cannabis had been rescheduled to Schedule III, social media erupted with celebrations. Some people genuinely believed federal legalization had arrived. Dispensary owners posted triumphant videos. Cannabis stocks briefly spiked.

The reality, as Sara Carter Bailey made clear today, is far more nuanced. Her statement was not a policy reversal or some kind of anti-cannabis broadside. It was a correction of a narrative that had run away from the facts. And for an industry that has been burned repeatedly by the gap between expectation and reality, this is a pattern that should feel painfully familiar.

The thing is, Bailey's statement is important not because it changes anything, but because it forces a conversation the cannabis world needs to have about what rescheduling actually accomplished and what enormous gaps remain in the federal approach.

What the April 23 DEA Order Actually Did

On April 23, 2026, the DEA published an order that moved certain categories of marijuana from Schedule I to Schedule III of the Controlled Substances Act. That order became effective on April 28. But here's the part that matters and the part that most headlines glossed over: the order was narrow. Very narrow.

Think of it this way. If you're a patient in a state with a medical marijuana program, and you're purchasing from a state-licensed dispensary, the product you're buying is now Schedule III under federal law. That's a meaningful change. It means the federal government formally recognizes that this product has accepted medical use and moderate to low abuse potential.

But if you're buying an eighth from a recreational dispensary in Colorado or picking up some gummies at a licensed adult-use shop in Michigan, that product is still Schedule I. Same category as heroin. Same federal penalties, at least on paper. The DEA essentially created a two-tier system where the exact same plant, sometimes the exact same product, sits in different schedules depending on the regulatory framework under which it was sold.

If that sounds confusing, that's because it is. This is what happens when you try to thread the needle between decades of prohibition and the reality that 40-plus states have some form of legal cannabis.

Schedule III vs Schedule I: The Split Nobody Expected

Most industry watchers expected that if rescheduling happened, it would be comprehensive. The whole plant, in all its forms, would move from Schedule I to Schedule III. Instead, the DEA took a surgical approach that has created one of the stranger regulatory landscapes in American drug policy history.

The 280E Tax Bombshell for Medical Operators

For all the confusion around the Schedule III move, there is one area where the change is immediate, tangible, and genuinely significant: taxes. Section 280E of the Internal Revenue Code has been the financial anvil hanging over the cannabis industry for years. It prevents businesses that traffic in Schedule I or Schedule II controlled substances from deducting ordinary business expenses on their federal tax returns.

With medical cannabis now in Schedule III, qualifying medical marijuana businesses can finally deduct rent, payroll, marketing costs, and all the other expenses that every other American business takes for granted. For companies that have been operating under effective tax rates of 50 to 70 percent, this is transformative. Some operators have estimated that 280E relief alone could turn money-losing operations into profitable ones overnight.

But here's the catch. Only businesses that exclusively or primarily deal in Schedule III cannabis, meaning state-licensed medical products, get this benefit. If you're a recreational-only operation, 280E still applies in full. And for dual-license holders, the accounting is about to get incredibly complicated. How do you allocate shared expenses between medical and recreational sales when one side is Schedule III and the other is Schedule I? The IRS hasn't issued guidance yet, and tax attorneys across the industry are scrambling to figure out the rules in real time.

Oklahoma's DEA Registration Warning

One of the more under-reported consequences of the Schedule III move came out of Oklahoma, where state officials warned medical cannabis operators that they now need to register with the DEA. This is a direct result of rescheduling, and it caught a lot of people off guard.

Here's the logic. Schedule I substances require DEA registration to handle, but because cannabis was operating in this gray zone where states had legalized it while the feds hadn't, most state-licensed operators never registered with the DEA. They didn't need to because the federal government had adopted a general hands-off approach.

Now that medical cannabis is explicitly Schedule III, the normal rules for handling Schedule III controlled substances apply. And those rules say that anyone who manufactures, distributes, or dispenses a Schedule III substance must hold a valid DEA registration. For Oklahoma, which has one of the largest medical cannabis markets in the country with thousands of licensed operators, this is a massive administrative undertaking.

The practical implications are significant. DEA registration means DEA oversight, record-keeping requirements, and the potential for DEA inspections. For an industry that has operated largely under state-level supervision, federal regulatory scrutiny is a new ballgame entirely. Some smaller operators may find the compliance burden overwhelming. And there are legitimate questions about whether the DEA has the infrastructure to process thousands of cannabis-related registrations in a timely manner.

The June 29 Expedited Hearing: What's Next

If you're reading all of this and thinking that the current split system is unsustainable, you're not alone. The DEA apparently agrees, because an expedited hearing has been scheduled for June 29 through July 15, 2026, to consider broader rescheduling of cannabis.

This hearing is where the real action will be. The April 23 order was, in many ways, a first step designed to provide immediate relief to the medical cannabis sector while the larger questions get worked out. The June hearing will address whether all cannabis, including recreational marijuana, should be moved out of Schedule I.

The expedited timeline is notable. Federal rulemaking processes typically move at glacial speed, with comment periods and hearings stretching over months or years. The fact that this hearing has been fast-tracked suggests there is political will to resolve the current inconsistency relatively quickly.

However, there are no guarantees about the outcome. The hearing could result in a recommendation to move all cannabis to Schedule III, which would be the most straightforward resolution. It could also result in a more complex tiered system, where different forms or potencies of cannabis receive different scheduling. Or it could stall, leaving the current awkward split in place for an extended period.

Industry stakeholders, advocacy groups, law enforcement organizations, and public health officials will all have the opportunity to present testimony. The scope and intensity of that testimony will likely shape not just the hearing's outcome but the broader trajectory of federal cannabis policy for years to come.

What Consumers Should Actually Know

So let's cut through the noise and talk about what this all means if you're a regular person who uses cannabis. The honest answer is that your day-to-day experience probably hasn't changed much since April 28, and it probably won't change much in the near term.

If you're a medical cannabis patient buying from a licensed dispensary in your state, your product is now technically Schedule III. That doesn't change what you can buy, how much you can possess, or where you can consume it. Those rules are still set by your state. What it does mean is that the federal government has formally acknowledged the medical legitimacy of what you're doing, which is symbolically significant even if it doesn't change your Tuesday afternoon dispensary run.

If you're a recreational consumer, nothing has changed at the federal level. Your purchases are still Schedule I, and you're still technically in violation of federal law every time you buy, possess, or use cannabis. The practical risk of federal prosecution for personal use remains extremely low, as it has been for years, but the legal exposure is unchanged.

The biggest near-term impact for consumers is likely to be on pricing. As medical operators benefit from 280E relief and potentially lower compliance costs, some of those savings may eventually trickle down to patients through lower prices. But don't expect that to happen immediately. The industry needs time to adjust to the new tax reality, and many operators will use the savings to shore up balance sheets before they start cutting prices.

What Operators Need to Do Right Now

If you're running a cannabis business, the to-do list coming out of this rescheduling is significant. First and foremost, talk to your tax attorney and your CPA immediately if you haven't already. The 280E implications are real and time-sensitive, and how you structure your medical vs. recreational accounting could have six or seven-figure consequences.

Second, pay attention to what your state is doing in response to the DEA order. Oklahoma's DEA registration warning is unlikely to be the last. If your state hasn't issued guidance yet, it probably will soon, and you need to be ready to comply.

Third, keep a close eye on the June 29 hearing. The testimony and recommendations that come out of those proceedings will shape the regulatory environment for the next several years. If your business is large enough to participate or submit comments, you should seriously consider doing so.

And finally, do not assume that the current situation is permanent. The split between Schedule I recreational and Schedule III medical cannabis is almost certainly a transitional arrangement, not an end state. Build your business plans with flexibility in mind, because the ground is going to shift again.

Frequently Asked Questions

Is all cannabis now Schedule III? No. Only state-licensed medical marijuana and FDA-approved marijuana products moved to Schedule III as of April 28, 2026. Recreational cannabis remains Schedule I.

Can I get in trouble for using recreational cannabis? Technically, yes. Recreational cannabis is still Schedule I under federal law. Practical enforcement risk for personal use remains very low, but the legal status has not changed.

What is the June 29 hearing about? The DEA has scheduled an expedited hearing from June 29 to July 15 to consider broader rescheduling of cannabis, potentially including recreational marijuana.

Do dispensaries need to register with the DEA now? Medical cannabis dispensaries and operators likely need DEA registration since medical marijuana is now a Schedule III substance. Oklahoma has already warned its operators about this requirement.

Does this affect cannabis banking? Schedule III classification for medical cannabis could improve banking access for medical-only operations, as banks face reduced legal risk serving businesses dealing in Schedule III vs. Schedule I substances. But recreational operations remain in the same banking limbo.

What about 280E taxes? Medical cannabis businesses that qualify under the Schedule III classification can now deduct standard business expenses, potentially saving significant amounts. Recreational-only businesses remain subject to 280E.